On July 23, 2025, Gilead Sciences' stock movement outperformed the S&P 500 gain, while the broader medical sector experienced losses.

2 reports, 1 independent Updated Jul 23

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

On July 23, 2025, Gilead Sciences' stock movement outperformed the S&P 500 gain, while the broader medical sector experienced losses.

Who's involved

What this event is mainly about

Gilead Sciences

Keep exploring

Part of

Zacks listed Gilead Sciences as a trending stock, noting that industry performance influences stock trends. All 2 developments

The entities involved

Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Sun 22:40
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Sat 01:51

Related events

Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.Sep 10

Coverage

Newest first; wire copies grouped

Jul 23ZacksGilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know Gilead Sciences (GILD) closed at $110.17 in the latest trading session, marking a +1.75% move from the prior day. This c
Jul 16ZacksHere's Why Gilead Sciences (GILD) Fell More Than Broader Market In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged